3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Terminated
2
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
2
Myeloid
2
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
10
Leukemia
7
Leukemia, Myeloid, Chronic-Phase
6
Leukemia, Myeloid
2
Gastrointestinal Stromal Tumors
2
Bone Marrow Diseases
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasms by Histologic Type
1
Neoplasms
1
Neoplasm, Residual
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Leukemia, Myeloid, Acute
1
Hematologic Neoplasms
1
Hematologic Diseases
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Squamous Cell
1
Blast Crisis
1
Interventions
venetoclax
3
Imatinib Mesylate
3
ponatinib
2
nilotinib
2
Dasatinib
2
Azacitidine
2
zileuton
1
thymoglobulin
1
pulrodemstat besilate
1
posaconazole
1
emvododstat
1
Transplantation
1
Standard of Care
1
Mycophenolic Acid
1
Methylprednisolone Hemisuccinate
1
Methylprednisolone Acetate
1
Methylprednisolone
1
Lenalidomide
1
IMC-EB10
1
Homoharringtonine
1
HhAntag691
1
Hematopoietic Stem Cell Transplantation
1
Decitabine
1
Cytarabine
1
Cyclosporine
1
CC 401
1
BID protein, human
1
Antilymphocyte Serum
1
AVE9633
1
3-(4-((4-chlorophenyl)sulfonyl)-4-(2,5-difluorophenyl)cyclohexyl)propanoic acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Terminated
×
Leukemia, Myeloid
×
nilotinib
×
Clear all
NCT02627677
2021-11-26
OPTIC-2L
Takeda
Phase 3
Terminated
44 enrolled
22 charts
NCT00519090
2011-11-07
ENEST
Novartis
Phase 3
Terminated
6 enrolled
6 charts